| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Eli Lilly inks cancer pact worth up to $5.9bn with Stipple Bio | ||
| Di | Pfizer CEO: 'China will be my major competition by 2030' | ||
| Di | Seawolf Therapeutics and Sanofi agree $1.2bn drug deal | ||
| Di | UK biotech sector calls on government to support sector's growth on home soil | ||
| Di | Lilly agrees to acquire Calytrix Bio for $1.5bn | ||
| Mo | J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences | ||
| Mo | RevMed CEO on tackling "complex" launch for wonder pancreatic drug | ||
| Mo | Flagship Pioneering expands to UK with £100m AI-native lab | ||
| Mo | Sofinnova Partners backs European life sciences sector with €725M raise | ||
| Mo | AstraZeneca secures FDA approval for Imfinzi combo in MIBC | ||
| Mo | FDA rejects Summit's ivonescimab application for lung cancer | ||
| Mo | HLTH 2026: Potential 2028 US presidential contender Mark Kelly warns pharma over profits | ||
| Fr | FDA puts commissioner's priority voucher framework on ice | ||
| Fr | Neurosterix pockets $105m to advance neuropsychiatry pipeline | ||
| Fr | BMS sets unified research and development structure for 2027 | ||
| Fr | Takeda begins US distribution of narcolepsy type 1 drug Orzeyful | ||
| Do | Eli Lilly beats Novo to oral China GLP-1RA market on NMPA approval | ||
| Do | Blackstone backs Pfizer's obesity ambitions with $1.5bn fund | ||
| Do | Beyond GLP-1RA's: Novel mechanisms and combos to shape future of obesity market | ||
| Do | FDA and EMA waive paediatric studies for Shanton's gout candidate | ||
| Do | Life-extending peptides are likely not around the corner | ||
| Do | Litmys and PharmaACE partner on pharma commercial forecasting | ||
| 11.11. | AstraZeneca acquires bacterial vaccine biotech, Omniose | ||
| 11.11. | Longevity sector ambitions outpace regulatory and investment frameworks | ||
| 11.11. | Moderna's CEO eyes Keytruda-eclipsing future for personalised cancer vaccine |